{
  "ticker": "MSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964319",
  "id": "02964319",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250701",
  "time": "0949",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l9yrspwwzj5j.pdf",
  "summary": "**Key Material Information:**  \n- **FDA alignment on BLA filing** for Revascor\u00ae (rexlemestrocel-L) in ischemic heart failure with reduced ejection fraction (HFrEF).  \n- **Accelerated approval pathway** confirmed for end-stage HFrEF patients with LVAD implantation.  \n- **BLA submission targeted by end of 2025**; alignment achieved on CMC, potency assays, and confirmatory trial design.  \n\n*Omitted: Background, forward-looking statements, and non-material operational details.*",
  "usage": {
    "prompt_tokens": 1715,
    "completion_tokens": 110,
    "total_tokens": 1825,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T23:53:38.579270"
}